Holen Sie sich die Stockscreener-App
32.31
1.58%
-0.52
Schlusskurs vom Vortag:
$32.83
Offen:
$32.83
24-Stunden-Volumen:
3.36M
Relative Volume:
0.75
Marktkapitalisierung:
$13.61B
Einnahmen:
$2.26B
Nettoeinkommen (Verlust:
$1.09B
KGV:
13.79
EPS:
2.3431
Netto-Cashflow:
$2.70B
1W Leistung:
-2.45%
1M Leistung:
+0.37%
6M Leistung:
+22.25%
1J Leistung:
+18.22%
1-Tages-Spanne:
$32.20
$32.93
1-Wochen-Bereich:
$32.20
$34.31
52-Wochen-Spanne:
$24.05
$34.31
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
32.31 | 13.96B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma - insights.citeline.com
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Man Group plc - MarketBeat
Point72 Asset Management L.P. Sells 277,630 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Two Sigma Investments LP Cuts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Holdings Trimmed by Captrust Financial Advisors - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Two Sigma Advisers LP Has $93.70 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Ethic Inc. - MarketBeat
Royalty Pharma at RBC Capital Markets: Strategic Funding Insights By Investing.com - Investing.com Nigeria
Transcript : Royalty Pharma plc Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 04 - marketscreener.com
Occudo Quantitative Strategies LP Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Raiffeisen Bank International AG Acquires New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives $42.50 Consensus PT from Analysts - Defense World
OMERS ADMINISTRATION Corp Trims Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Patient Capital Management LLC Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma completes major acquisition By Investing.com - Investing.com Canada
Royalty Pharma completes major acquisition - Investing.com
Balyasny Asset Management L.P. Purchases Shares of 59,755 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Bank of America Corp DE - MarketBeat
Royalty Pharma Completes RP Management Acquisition - citybiz
Baird Financial Group Inc. Acquires New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Deutsche Bank AG Buys 847,704 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Morgan Stanley Initiates Coverage on Royalty Pharma (NASDAQ:RPRX) - Defense World
Royalty Pharma (NASDAQ:RPRX) Stock Rating Upgraded by StockNews.com - MarketBeat
Royalty Pharma Closes Acquisition of External Manager - marketscreener.com
Royalty Pharma plc Completes Internalization of Management Structure with Overwhelming Shareholder Support - Nasdaq
Royalty Pharma Completes the Acquisition of Its External Manager - The Manila Times
Royalty Pharma Completes The Acquisition Of Its External Manager - marketscreener.com
Royalty Pharma's Major Transformation: External Manager Acquisition Promises Significant Cost Savings - Stock Titan
Royalty pharma projects 6-12% growth in 2025 portfolio receipts with $2B share buyback plan - MSN
Morgan Stanley reinstates Royalty Pharma with Overweight rating By Investing.com - Investing.com Nigeria
Morgan Stanley Reinstates Royalty Pharma (RPRX) at Overweight - StreetInsider
D. E. Shaw & Co. Inc. Purchases 228,964 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma at Bank of America 2025 Healthcare: Strategic Growth Insights - Investing.com Nigeria
Learn to Evaluate (RPRX) using the Charts - news.stocktradersdaily.com
BNP Paribas Financial Markets Makes New $41.96 Million Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Axa S.A. Acquires 138,017 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Crestline Management LP Acquires 79,532 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Bridgefront Capital LLC Invests $311,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma to Present at Upcoming Investor Conferences - The Manila Times
Stifel Financial Corp Has $438,000 Stake in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Royalty Pharma (NASDAQ:RPRX) Rating Increased to Buy at StockNews.com - Defense World
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
6.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):